Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation AHA 2018

REDUCE-IT Trial: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L Bhatt

November 16, 2018

Presentation AHA 2018

Ticagrelor vs Aspirin in Patients undergoing Coronary-Artery Bypass Grafting

Presenter: Heribert Schunkert

November 14, 2018

Presentation AHA 2018

REGROUP Trial: A Prospective, Randomized TRial Comparing Endoscopic vs. Open Vein Grafts in CABG Surgery

Presenter: Marco A. Zenati

November 13, 2018

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

Alert-Based Computerized Decision Support to Increase Anticoagulation Prescription Prevents Stroke and Myocardial Infarction in High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)

Presentation AHA 2018

High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)

Presenter: Gregory Piazza

November 11, 2018

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Presentation AHA 2018

DECLARE - TIMI 58

Presenter: Stephen Wiviott

November 11, 2018

Advertisement

REDUCE-IT Trial: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Ticagrelor vs Aspirin in Patients undergoing Coronary-Artery Bypass Grafting

REGROUP Trial: A Prospective, Randomized TRial Comparing Endoscopic vs. Open Vein Grafts in CABG Surgery

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

DECLARE - TIMI 58

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content